Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

Werewolf debuts with $56M to develop tumor-activated biologics

November 20, 2019 11:31 AM UTC
Updated on Nov 21, 2019 at 1:19 AM UTC

Emerging from stealth with a $56 million series A round, Werewolf Therapeutics is aiming to increase the therapeutic window of cytokines and immuno-stimulatory antibodies by masking their activity until they reach the tumor microenvironment.

MPM Capital and Longwood Fund co-led the round with participation from Taiho Ventures, Arkin Bio Ventures, UPMC Enterprises and DC Investment Partners...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article